Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system by unknown
RESEARCH ARTICLE Open Access
Stable high-level expression of factor VIII in
Chinese hamster ovary cells in improved
elongation factor-1 alpha-based system
Nadezhda A. Orlova1, Sergey V. Kovnir1, Alexandre G. Gabibov2 and Ivan I. Vorobiev1*
Abstract
Background: Recombinant factor VIII (FVIII), used for haemophilia A therapy, is one of the most challenging among the
therapeutic proteins produced in heterologous expression systems. Deletion variant of FVIII, in which the entire domain B
is replaced by a short linker peptide, was approved for medical use. Efficacy and safety of this FVIII deletion variant are
similar to full-length FVIII preparations while the level of production in CHO cells is substantially higher.
Typical levels of productivity for CHO cell lines producing deletion variant FVIII-BDD SQ, described elsewhere, are 0.5–2 IU/
ml, corresponding to the concentration of FVIII of about 0.2 μg/ml. Using standard vectors based on the cytomegalovirus
promoter (CMV) and the dihydrofolate reductase cDNA we have previously obtained the cell line secreting 0.5 IU/ml of
FVIII-BDD, which roughly corresponds to the previously published data.
Results: An expression system based on CHO genomic sequences including CHO-EEF1A promoter and Epstein-Barr
virus terminal repeat fragment allowed us to achieve 80-fold increase in the production level as compared with the
conventional expression system based on the CMV promoter.
Immediately after the primary selection FVIII -producing cells secreted 5–10 IU/ml of FVIII-BDD, and after multi-stage
methotrexate-driven amplification a stable clonal line 11A4H was selected, secreting 39 IU/ml of FVIII-BDD in the simple
batch culturing conditions, which considerably exceeds known indicators for industrial producers of this protein. In
contrast to other FVIII-BDD producing lines 11A4H accumulates low proportion of the secreted FVIII on the membrane.
Its productivity may be further increased approximately two-fold by adding sodium butyrate and butylated
hydroxyanisol to the culture medium.
A five-stage purification process for the factor VIII was employed. It allowed isolation of the intact FVIII-BDD as was
confirmed by mass spectrometry. Purified FVIII-BDD has a specific activity of 11,000 IU/mg, similar to known recombinant
FVIII drugs.
Conclusions: The recombinant FVIII-BDD was produced in CHO cells without addition of any animal-derived materials,
purified and characterized. Novel genetic constructions for the expression of heterologous proteins combined with
optimized cultivation method allowed to obtain the secretion level of biologically active recombinant FVIII increased by
almost ten times as compared with the previously published analogues.
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Background
Blood clotting factor VIII (FVIII) is a major non-
enzymatic component of the positive amplification loop
in the intrinsic coagulation pathway [1]. It is present in
the bloodstream mostly in the non-covalent complex
with its chaperone von Willebrand factor (vWF). In the
case of a blood coagulation event, FVIII undergoes spe-
cific proteolytic cleavage by the thrombin, converting it
to the activated FVIII (FVIIIa) [2]. FVIIIa dissociates
from vWF, binds to the surface of acidic cell membranes
of activated platelets, recruits binding of the activated
factor IX (FIXa) and the factor X (FX) to the ternary
complex “X-ase” (or tenase), promotes specific cleavage
of the FX by the FIXa to the activated FX (FXa) and al-
lows the release of the FXa from the X-ase complex [3].
Natural human FVIII is a large glycoprotein with mul-
tiple size variants, ranging from 190 to 300 kDa. Circu-
lating FVIII is predominantly present in the two-chain
form; the heavy chain of FVIII comprises the domains
A1-A2-B and the light chain the domains A3-C1-C2 [4].
Heavy and light chains of FVIII are held together non-
covalently and the coordinated copper ion is considered
to be crucial for maintaining the integrity of the di-chain
FVIII molecule [5]. The entire B-domain of the FVIII is
expendable for its hemostatic function; a significant pro-
portion of the natural FVIII in circulation lacks the B-
domain, which is removed by proteolysis [6].
Decreased level of FVIII or loss of its procoagulant func-
tion due to genetic abnormalities results in the bleeding
disorder hemophilia A. Prevalence of hemophilia A is about
1:5000 men and regular infusions of natural or recombinant
FVIII are the only effective treatment of this disease. Func-
tionally active recombinant FVIII may be obtained only by
secretion from cultured mammalian cells due to the com-
plex pattern of post-translational modifications, including
glycosylation and sulfation of several tyrosine residues [7],
although the isolated light chain of FVIII may be expressed
in methylotrophic yeasts [8]. There are two commercialized
full-length recombinant FVIII products, one of them is
based on BHK cells, cultured in the presence of human
plasma proteins [9] and other is based on CHO cells, se-
creting FVIII and vWF [10]. Both these expression systems
have relatively low volumetric productivity due to the low
stability of the full-length FVIII even in the presence of
vWF. The third variant of the commercially manufactured
recombinant FVIII is the truncated protein, lacking the en-
tire B-domain. It is secreted into the protein-free culture
medium by CHO cells and does not require the presence
of vWF [11]. All three preparations of recombinant FVIII
are equally effective in the treatment of hemophilia A [12].
There are several factors, limiting the expression of
FVIII in heterologous systems, including transcription
silencers in its mRNA [13, 14], retardation in endoplas-
mic reticulum [15], re-adsorption of the secreted FVIII
to the cell membranes [16] and its instability in the cul-
ture medium. Cell lines expressing FVIII with increased
specific productivity still are of great practical import-
ance since the cost of production of recombinant FVIII
for clinical use may be significantly cut by increasing its
concentration in the culture medium.
Recently we have developed a specialized plasmid vec-
tor p1.1 for stable high-level expression of heterologous
proteins in CHO cells and confirmed that it enables a
relatively rapid increase of cells productivity after
methotrexate-driven gene amplification [17]. Here we
report the use of this vector for the development of
highly productive cell lines, stably secreting functionally
active B-domain deleted FVIII.
Methods
Cloning of p.1.1-F8BDD
The DNA fragment encoding the FVIII-BDD ORF with
Kozak consensus sequence was obtained by PCR using
primers AD-8-AbsF (5’-ACC TCG AGG CCG CCA CCA
TGG AAA TAG AGC TCT CC-3’) and AD-ONheI-R (5’-
AAG CTA GCT CAG TAG AGG TCC TGT GCC-3’),
the plasmid pOptivec/F8BDD [18] as a template, and Ter-
sus polymerase mix (Evrogen, Moscow, Russia). The PCR
product was subcloned into T-vector, sequenced using the
primers to FVIII ORF listed in [18] and then inserted into
the expression vector p1.1 (described in [17]) using AbsI
(Sibenzyme, Novosibirsk, Russia) and NheI (Fermentas,
Vilnius, Lithuania) restriction enzymes. Resulting expres-
sion plasmid p1.1-F8BDD for the transfection was purified
by EndoFree Plasmid MaxiKit (Qiagen, Valencia, CA,
USA) and sequence-verified.
Cell culture
CHO DG-44 (Cat. No. A1100001, Invitrogen, Carlsbad,
CA, USA) cell line, adapted to suspension culture in a
chemically defined medium was used. Cells were cul-
tured in Erlenmeyer flasks (VWR International, Radnor,
PA, USA) in 30 ml of CD DG-44 medium (Invitrogen)
supplemented with 8 mM L-glutamine (Invitrogen) and
0.18% of surfactant Pluronic F-68 (BASF Inc., Florham
Park, NJ, USA) at 37 °C, 8% CO2, with stirring on an or-
bital shaker at 130 rpm. Cells were passaged every 2–3
days at the culture density 1.2 x 106 live cells per ml,
and diluted with fresh medium in a ratio of 1:4.
Transfection was performed using Fugene HD (Origen
Biomedical, Austin, TX, USA), in a ratio of 18 μg of
plasmid DNA per 1.5 × 107 cells in 30 ml of culture
medium. Plasmid for the transfection was linearized by
the PvuI or used in the supercoiled form. Transfection
efficiency was determined by fluorescence microscopy
48 h post-transfection for control plasmid mixture
(p1.1-F8BDD plasmid mixed 95:5 by weight with green
fluorescent protein encoding plasmid pEGFP-N2). After
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transfection cells were cultured for 48 h without
medium exchange, then transferred into selective
medium ProCHO 5 (Lonza, Basel, Switzerland) and
grown until cell viability was restored to 90% (15–20
days). During the cultivation in selective medium, cells
were passaged every 3–5 days to the cell density 5 × 105
cells/ml or less until positive growth was observed. After
this, cells were passaged every 3 days at the seeding
density 3 × 105 cells/ml. Stably transfected cell popula-
tion from the suspension culture was transferred to the
96-well plates with the culture medium Ex-Cell CHO
Cloning Medium (Sigma-Aldrich, St. Louis, MO, USA),
supplemented by the 8 mM of L-glutamine and 50–400
nM MTX. The growth of colonies was monitored at the
10th and 14th days of cultivation. Growth-positive wells
were screened by ELISA, culture medium in antigen-
positive wells was changed and colonies were grown
close to the confluence. Alternatively, at 48 h post-
transfection cells were seeded into 96-well plates at a
density of 10,000 cells per well, 200 μl per well of AOF
Ex-Cell CHO Cloning Media (Sigma-Aldrich) medium
with 50 nM MTX and 8 mM of L-glutamine at 37 °C,
5% CO2. Cells were maintained as described above.
Cells from most productive colonies obtained by both
techniques were transferred to 48-well plates, cultivated
for 5 d and screened again by ELISA. Best secreting oli-
goclonal lines were further expanded and readapted to
suspension growth in ProCHO 5 medium with 8 mM L-
glutamine during three sequential passages in 24-, 12-
and 6-well plates.
FVIII concentration in the culture medium was mea-
sured 48 h post-transfection and at the end of the selec-
tion for stable transfectants. Oligoclonal cell line with the
highest level of secreted FVIII, obtained in the presence of
50 nM MTX, was used for further amplification of bicis-
tronic FVIII-dhfr cassette. It was grown in the ProCHO 5
medium with 8 mM of L-glutamine in the presence of in-
creasing concentrations of methotrexate (MTX). Each
amplification step lasted for 14–25 days until cell viability
restored to 90%. Concentration of secreted FVIII was
measured by ELISA and/or clotting test at the end of each
step. Transgene-amplified oligoclonal cell line, obtained
by the highest MTX selection pressure possible (4 μM)
was cloned by limiting dilution in AOF Ex-Cell CHO
Cloning Media (Sigma-Aldrich) with 8 mM alanyl-
glutamine (Invitrogen) and HT (hypoxanthine/thymidine)
supplement (Invitrogen), without MTX. Cells were seeded
into 96-well plates at a density of 0.5 cells per well, 200 μl
of medium per well at 37 °C, 5% CO2. The growth of sin-
gle colonies was monitored at the 10th and 14th days of
cultivation. The colonies were screened by ELISA, culture
medium in positive wells was changed and colonies were
grown close to the confluence. According to the results of
the subsequent ELISA of actively growing colonies the
most productive of them were transferred to 48-well
plates. Clonal lines with the best levels of secretion were
further expanded and readapted to suspension growth in
ProCHO 5 medium with 8 mM L-glutamine during three
sequential passages in 24-, 12- and 6-well plates.
Conditioned medium from 6-well plates was analyzed by
ELISA. The top three cell lines were moved to Erlenmeyer
flasks and evaluated by growth rate and specific productiv-
ity. Preparative batch cultivation was conducted in 500 ml
Erlenmeyer flasks, 125 ml of culture medium per flask.
Cells were seeded at a concentration of 2.5 × 105 cells/ml
and cultured without medium change to a density of 3 ×
106 cells/ml (4–5 days).
ELISA
Concentration of the factor VIII antigen (FVIII:Ag) was
measured by ELISA using polyclonal antibodies to FVIII
(LifeSpan BioSciences, Seattle, WA, USA) at 50 ng per
well and specific MAb A2 to FVIII heavy chain described
in [18]. Serial dilutions of normal calibrated human
plasma (NPO Renam, Moscow, Russia) in PBS with 1%
bovine serum albumin (BSA) were used as a standard.
Samples were also diluted in PBS with 1% BSA.
Clotting assays
One stage clotting assay with chromogenic substrate was
performed by the TECHNOCHROM® F VIII:C kit
(Technoclone GmbH, Vienna, Austria); two stage clot-
ting assay was performed by the optical coagulation
analyzer ThromboScreen 400c (ThermoFisher Scientific,
USA) and the Factor VIII- test reagent kit (NPO
Renam), using normal calibrated human plasma (NPO
Renam) as the initial standard and one stage assay-
characterized sample of the FVIII-BDD preparation as
the working standard. Specific activity of several FVIII-
BDD samples was 1.7 times lower in the two-stage assay
than in the one-stage assay if human plasma was used as
the activity standard. Samples were diluted with the
imidazole buffer with 1% BSA (NPO Renam).
Medium modifications
Effect of alkanoic acids in the culture medium on FVIII
secretion was assessed in batch cultures, seeded as
3.75 × 105 cells/ml and cultured for 3 days unless stated
otherwise. Sodium butyrate and sodium propionate were
dissolved in water at 1 M and adjusted to the pH 7.2 by
HCl prior to addition to the culture medium. Antioxi-
dant butylated hydroxyanisole was dissolved in DMSO
at 2.5 M prior to addition to the culture medium, final
concentration 0.1 mM; addition of dichlorofluorescein
(DCF, Invitrogen) and subsequent flow cytometry ana-
lysis for oxidative stress level was performed as de-
scribed in [19].
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Oxidative stress induction and flow cytometry
Cells of the 11A4H line were seeded as 3.5 × 105 cells/ml
in the protein-free ProCHO-5 medium and cultivated
for 4 days in the shake flask. On 3rd and 4th day 1 × 106
cells were sampled. Then samples were stained with
5 μM of CM-H2-DCF-DA (Invitrogen) for 20 min on ice
and counterstained with 1.5 μM propidium iodide just
before flow cytometry analysis on Cytomics FC500 in-
strument (Beckman Coulter). Direct reads were gated on
FS/SS scatter against intact control cells sample and
then subsequently gated for propidium iodide exclusion
(channel FL-3 620 nm). Generation of ROS were
assessed as green fluorescence of activated DCF by
measuring in FL-1 (525 nm) channel for 105 gated cell
reads, every obtained FL-1 scatter histogram were uni-
modular, mean values were calculated for core 5 ml of
intact cell culture with H202 in final concentrations
10 μM, 100 μM and 1000 μM directly prior to live
staining.
Quantitative PCR, PCR, RT-PCR
Copy number of the expression cassettes in the genome
was determined by the quantitative real-time-PCR (qPCR).
A calibration curve was prepared using serial dilutions of
highly purified p1.1-F8BDD plasmid. Genomic DNA was
isolated by Wizard SV Genomic DNA Purification System
(Promega, USA) and quantified by the Qubit Fluorometer
(Invitrogen), using dsDNA HS kit (Invitrogen) and exter-
nal DNA concentration standard, prepared in-house from
the highly purified plasmid DNA, quantified by UV spec-
trophotometry. Concentration of the genomic DNA was
validated by control qPCR with primers to PPIB gene re-
gion, presumably unique to the CHO cells genome accord-
ing to the BLAST search results. Samples of genomic
DNA with the determined copy numbers of PPIB less than
0.3 per haploid genome or more than 2.0 were discarded.
Weight of one CHO haploid genome was established as
3 pg according to [20].
The mRNA levels were assayed by reverse transcrip-
tion and quantitative PCR (RT-qPCR). Total RNA was
isolated by the RNeasy Mini Kit (Qiagen), its concentra-
tion was determined by UV spectroscopy, purification
quality was confirmed by monitoring the A260/A280 ra-
tio (1.8–2.0); integrity was verified by electrophoresis in
1% agarose gel. The cDNA was synthesized with the re-
agent kit Mint (Evrogen) using 1 μg of total RNA per
sample. The ΔΔCq method [21] was used to calculate
mRNA expression relative to β-actin.
Primers (listed in Additional file 1: Table S1) were de-
signed by the Beacon Designer v7.51 program (PREM-
IER Biosoft International, Palo Alto, CA). The unique
primers allowing selective amplification of the expres-
sion cassette were chosen for the genome copy number
analysis, and primers located in the different exons or at
the exon junctions were used for mRNA expression level
analysis.
QPCR was performed using qPCRmix-HS SYBR reac-
tion mixture (Evrogen) and iCycler iQ thermocycler (Bio-
Rad, USA). Calculations of threshold cycles, calibration
curves, PCR efficiency and copy numbers were made by
the iCycler Iq4 program. All determinations were repeated
3 times, in 3–5 replicates, sample volume 25 μl.
PCR analysis of the whole FVIII ORF area was per-
formed for genomic DNA and cDNA in the essentially
same conditions. Templates were taken as 10 ng per tube,
reaction volume was 10 μl. Primers AD-8-AbsF and AD-
ONheI-R, described in the Cloning subsection, were used;
Encyclo PCR kit (Evrogen) was employed. Temperature
gradient was from 53 °C to 68 °C. Amplification program
was 3’ at 95 °C; 25 cycles as 15” at 95 °C, 53–68 °C for 15”,
72 °C for 3’. Final elongation was 72 °C for 5’. Amplifica-
tion products were electrophoresed on 0.8% agarose gels
and stained with ethidium bromide.
Southern blot hybridization
Biotinylated probes for Southern blotting were prepared
by the Biotin DecaLabel DNA Labeling Kit (Fermentas).
Template for the probes was pAL-ID plasmid (contain-
ing regions present in expression plasmids p1.1 includ-
ing origin of replication, a beta-lactamase gene, EMCV
IRES, DHFR ORF [17]) or a PCR product corresponding
to the fragment of FVIII-BDD ORF. Genomic DNA was
digested with EcoRI (Fermentas) for 16 h, precipitated
by ethanol, separated by 0.8% agarose gel. Gel transfer to
an Amersham Hybond-N+ membrane (GE Healthcare,
USA) was performed according to the manufacturer’s
protocol in 20x SSC buffer (3 M NaCl, 0.3 M Na3-
C6H5O7) for 16 h. DNA was fixed by heating the dried
membranes at 80 °C for 2 h. Prehybridization and
hybridization were conducted according to [22] in the
buffer containing 7% SDS, 0.5 M Na2PO4, pH 7.2, 1%
BSA for 16 h at 65 °C. Membrane was washed according
to the manufacturer’s protocol and stained by Biotin
Chromogenic Detection Kit (Fermentas).
SDS-PAGE and immunoblotting
Samples of conditioned medium were clarified by centri-
fugation and concentrated 30 times by precipitation with
trichloroacetic acid. Cell lysates were prepared using a
modified RIPA buffer (50 mM Tris -HCl, pH 7.4, 1%
NP- 40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM Na-EDTA) with protease inhibitor cocktail
(Sigma-Aldrich) and normalized to total protein concen-
tration, determined by QuantiPro ™ BCA Assay Kit
(Sigma-Aldrich). Samples were separated by electrophor-
esis in 7.5% denaturing polyacrylamide gel, sample load
was 10 μg per well for cell lysates and the equivalent of
0.5 ml of conditioned medium. Gel slabs were stained by
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colloidal Coomassie stain (Fermentas) according to man-
ufacturer's procedure or used for blotting. Transfer to
the membrane, blocking, hybridization and staining were
performed as described previously [18].
Purification of FVIII
Purification of FVIII from the cell culture supernatant
was carried out as described in [23] with changes.
All solutions used for the purification, except the final
composition, contained 0.02% Tween-80. To the condi-
tioned culture medium or cell suspension, NaCl was
added to 0.3 M and CaCl2 to 27 mM. The resulting sus-
pension was incubated for 30 min with stirring at 37 °C,
clarified by centrifugation, supplemented with 10 mM of
L-histidine pH 7.0 and 0.02% of Tween-80 and applied
in 100 ml portions to the 1 ml HiTrap Capto MMC col-
umn (GE Healthcare), equilibrated with a solution 1-A
(0.3 M NaCl, 10 mM CaCl2, 10 mM L-histidine,
pH 7.0), flow rate 1 ml/min.
Column was washed by 10 volumes of solutions 1-B,
1-C and 1-D at 2 ml/min. Solution 1-B contained 1 M
NaCl, 50 mM CaCl2, 50 mM L- histidine, pH 6.5. Solu-
tion 1-C contained 0.1 M NaCl, 50 mM CaCl2,
50 mM L-histidine, pH 6.5. Solution 1-D contained
0.3 M NaCl, 10 mM CaCl2, 10 mM L-histidine,
0.25 M L-arginine-HCl, 10% ethylene glycol, pH 6.5.
FVIII was eluted at 1 ml/min by the solution 1-E (0.3 M
NaCl, 20 mM CaCl2, 20 mM L- histidine, 0.8 M L-
arginine-HCl, 50% ethylene glycol, pH 6.5).
Eluted FVIII solution was diluted 8-fold with a solu-
tion 2-A (10 mM NaCl, 10 mM L-histidine, 10 mM
CaCl2, pH 6.5) and applied to the 1 ml Tricorn 5/50 col-
umn (GE Healthcare) with the SP Sepharose FF (GE
Healthcare), equilibrated with a solution 2-B (0.15 M
NaCl, 10 mM L- histidine, 10 mM CaCl2, pH 6.5), flow
rate 2 ml/min. Column was washed with 20 ml of the
solution 2-B and FVIII was eluted by the solution 2-C
(0.34 M NaCl, 35 mM CaCl2, 45 mM L-arginine-HCl,
0.2 M sorbitol, 10 mM L-histidine, pH 6.5). Resulting so-
lution of the semi-purified FVIII was immediately frozen
in liquid N2 and stored in the −80 °C freezer.
Thawed FVIII solution was applied on the 1 ml Tri-
corn 5/50 column, filled with the immunoaffinity resin
VIII Select (GE Healthcare) at 0.2 ml/min. Prior to the
application of the sample, the column was equilibrated
with the solution 3-A (0.3 M NaCl, 20 mM CaCl2,
20 mM L- Histidine, pH 6.5). The column was washed
sequentially at a rate of 2 ml/min by 10 ml of the solu-
tion 3-A and 3 ml of the solution 3-B (1 M NaCl,
20 mM CaCl2, 20 mM L-Histidine, pH 6.5). FVIII was
eluted with the solution 3-C (1.5 M NaCl, 20 mM CaCl2,
20 mM L- Histidine, 50% ethylene glycol, pH 6.5).
Eluate was diluted 15-fold with the solution 4-A
(10 mM NaCl, 10 mM L- histidine, 10 mM CaCl2, pH 6.5)
and applied at 2 ml/min to the 1 ml HiTrap Capto Q col-
umn (GE Healthcare), equilibrated with the solution 4-B
(0.1 M NaCl, 0.02 M L-histidine, 20 mM CaCl2, pH 6.5).
Column was washed with 20 ml of the 4-C solution
(0.3 M NaCl, 20 mM L-histidine, 20 mM CaCl2, pH 6.5).
Elution was performed by the 4-D solution (0.4 M NaCl,
0.02 M CaCl2, 20 mM L-histidine, pH 6.5).
FVIII solution was applied in 2 ml portions at 0.4 ml/
min flow rate to the size exclusion column Tricorn 10/300
Superdex 200 (GE Healthcare), equilibrated with the 5-A
solution(9 g/L NaCl, 0.25 g/L CaCl2, 1.5 g/L L-histidine,
0.01% Tween-80, 3 g/L sucrose, pH 7.0) at the flow rate
1 ml/min. Monomer of the FVIII in the long-term storage
solution was collected in the final volume of 5–8 ml, di-
vided into small aliquots, frozen in liquid N2 and stored
frozen for further analysis.
Mass spectrometry
Coomassie-stained bands of FVIII chains were cut from
the polyacrylamide gel, washed twice (to remove the dye)
with 100 μl of 40% acetonitrile in 0.1 M NH4HCO3 for
20 min at 37 °C, dehydrated by 100 μl of acetonitrile and
completely dried in vacuo. Four μl of 15 μg/ml modified
trypsin solution (Promega) in 50 mM NH4HCO3 added to
each 3–4 mm3 gel piece. Hydrolysis was carried out for
5 h at 37 °C, then 7 μl of 0.5% trifluoroacetic acid (TFA)
in 10% aqueous acetonitrile solution was added and mixed
thoroughly. The upper layer of the solution above the gel
was used for MALDI-TOF analysis.
2 μl aliquots of the peptide mixtures were mixed with
0.5 μl of 2.5-dihydroxybenzoic acid solution (Aldrich,
20 mg/ml in 20% aqueous acetonitrile, 0.5% TFA), ap-
plied to target spots and air dried.
Mass spectra were obtained on a MALDI-TOF instru-
ment UltrafleXtreme (BrukerDaltonics, Germany) in the
positive ion mode with the reflectron. For each sample
analyzed the accuracy of the monoisotopic mass mea-
surements was maintained as at least 0.003% (30 rrm) by
the calibration on trypsin autolysis peaks. Spectra were
obtained in the mass range 700–4500 m/z. Peptide map-
ping was conducted using the GPMaw program (Light-
house data, Denmark).
Results
Establishment and characterization of BDD-FVIII producing
cell line
The expression construct p1.1-F8-BDD [GenBank:
KY682701] was obtained by ligating the FVIII-BDD SQ
ORF preceded by the Kozak consensus sequence into
expression vector p1.1. Natural FVIII UTRs were com-
pletely removed; therefore in the resulting expression
construct, FVIII ORF was entirely relocated into the
context of EEF1A1 gene (Fig. 1a).
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The FVIII:Ag level for the CHO DG-44 cells transi-
ently transfected with this plasmid in the supercoiled
form was 9 mIU/ml. The observed low level of FVIII:Ag
in the transiently transfected cells corresponds to the
low transfection efficiency, not exceeding 3% for the 16
kbp plasmid used. Meanwhile, CHO DG-44 cells stably
transfected with the CMV promoter-based plasmid
pOptivec/F8BDD displayed 2-fold lower FVIII:Ag level
under the same growth conditions [18] despite higher
transfection efficiency. Transfection of cells by the line-
arized expression plasmid p1.1-F8-BDD gave no detect-
able product 48 h post-transfection and no stably
transfected cells after 3 weeks of selection.
Two selection strategies were used for transfected
cells (cell lines generation scheme is depicted in the
Additional file 2: Figure S1). Generation of a stably
transfected population in suspension culture in the ab-
sence of both MTX and HT with subsequent selection
of oligoclonal lines in adherent culture or direct selec-
tion of stably transfected oligoclonal lines in adherent
culture immediately after transfection.
Stably transfected population (with FVIII:Ag level 134
mIU/ml) was plated into 96-well plates in the presence
of 50–400 nM MTX. Multiple FVIII:Ag-positive colonies
were observed in all cases (data not shown). It should be
noted that most of wells in the plates with 50–200 nM
MTX in the culture medium gave multiple colonies, but
in the case of 400 nM MTX supplementation the pro-
portion of wells with growing colonies dropped to less
than 10% from total. Subsequently, the ten most pro-
ductive wells in the plates with 50, 100 and 200 nM
MTX were chosen from 200–300 wells with actively
Fig. 1 Expression plasmid map, productivity of primary oligoclonal cell lines and long-term secretion rate dynamics of the selected clonal line. Panel a —
map of the expression plasmid, CHO EEF1A1 DFR – downstream flanking area of the EEF1A1 gene, UFR – upstream flanking area; EBV TTR – fragment of
the long terminal repeat from the Epstein-Barr virus; pUC ori – replication origin; bla, bla prom – ampicillin resistance gene and the corresponding
promoter; CHO EEF1A1 prom, intr1 – promoter and the first intron of the EEF1A1 gene; F8BDD ORF – open reading frame of the FVIII gene with the BDD
deletion; pA – polyadenylation signal. Positions of qPCR amplicons “F8B” and “ID” are marked by red and blue triangles, amplicon lengths are not to scale.
Panel b – culture medium samples taken from 96-well plates, testing was done when first 10% of the wells reached confluence; panel c – selected cell
lines readapted to suspension culture and tested at 1.2 × 106 cells/ml. Panel d - periodic culturing of the 11A4H cell line. Cells were passaged every third
day, FVIII:C titer was measured after 3 days of culture. Stated concentrations of the MTX were used in the corresponding selection of cell cultures. Results
are means, error bars represent standard deviation, n= 2. Raw data for figures are presented in corresponding Additional file 3
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growing colonies and the 10 most productive wells for
plates with 400 nM MTX supplementation were chosen
from less than 40 wells with colonies. In these condi-
tions, 200 nM MTX supplementation resulted in the
sharp increase of the maximal titer in first 10 most pro-
ductive wells (Fig. 1b).
For direct selection transiently transfected cells were
seeded 48 h post-transfection into 96-well plates in the
presence of 50 nM MTX and grown in the same manner.
Cells from the most productive wells, obtained by se-
lection and subsequent amplification in the presence of
200 nM MTX or by direct selection with 50 nM MTX,
were expanded and re-adapted to suspension culture.
Levels of FVIII:Ag in the culture medium (Fig. 1c)
ranged from 5 to 10 IU/ml which is comparable to typ-
ical published values for clonal cell lines producing
FVIII-BDD [24]. Thus one-step transgene amplification
under adherent conditions and direct selection of transi-
ently transfected cells in the presence of 50 nM MTX
resulted in oligoclonal cell lines, secreting FVIII-BDD in
the range of 2–8 IU/ml.
Oligoclonal line 3-B8, obtained by the direct selection
in the presence of 50 nM MTX and secreting mostly the
intact two-chain form of FVIII-BDD and virtually no de-
graded FVIII chains, according to Western blot data
(data not shown), was selected for further amplification
in the suspension culture.
Significant decrease of cell viability and inhibition of cell
growth rate were detected for the 3-B8 cell line at the
MTX level 1 μM. After gradual elevation of MTX concen-
tration to 8 μM, cell viability above 85% was not achieved
after 20 days of cultivation and maximal sustainable level
of MTX was 4 μM. No significant change in the FVIII-
BDD concentration was detected while increasing MTX
from 1 μM to 4 μM (Table 1), but we suggested that
higher level of the MTX may give rise to cell clones with
higher specific productivity. For this reason we choose the
oligoclonal cell line obtained in the presence of 4 μM
MTX for clonal cell lines generation by limiting dilution.
Cells were plated into twenty 96-well culture plates in the
absence of MTX and in the presence of HT, resulting in
361 single colonies. The most productive colonies were ex-
panded and re-adapted to suspension culture conditions.
Three lead cell lines were selected and further ex-
panded to shake flask cultures. The best clonal line
11A4H had specific productivity of 14.2 μIU/cell/d and
acceptable doubling time of 28.5 h. Batch culture of
11A4H in shake flask, seeded at 3 × 105 cells/ml in the
protein-free ProCHO medium gave a maximal concen-
tration of FVIII:C 39 ± 3 IU/ml at day 4, with final viable
cell count (VCD) of 3.5 × 106 cells/ml and viability over
85%. Further culturing without medium change resulted
in sharp drop in FVIII:C level and subsequent drop in
cell concentration and viability (data not shown).
Perfusion-like culturing was performed by seeding cells
in fresh culture medium at 1.5 × 106 cells/ml and changing
medium daily by centrifugation and subsequent resuspen-
sion of the cell pellet in the fresh medium. In these condi-
tions, FVIII:C level was in the range of 40–60 IU/ml for
several days. We suggest that the observed increase of
FVIII:C level in perfusion-like culture is due to the shorter
time the secreted protein remained in culture medium ex-
posed to proteases.
Since MTX was removed from the culture media at the
stages of cell cloning and expansion, we expected that the
resulting clonal cell line would maintain a high level of
FVIII secretion for a sufficiently long time needed for the
creation of cell banks and subsequent industrial manufac-
turing of the FVIII protein. For the 11A4H cell line the ob-
served specific level of FVIII secretion (ratio of FVIII:C
and VCD) showed no tendency to decrease during 120 days
of cultivation (at least 70 generations) in the absence of
MTX (Fig. 1d).
The transgene copy number in the genome of the cell
lines expressing FVIII was determined by qPCR. Two
transgene-specific areas of the integrated genetic cassette
were used for analysis — SQ linker region of the FVIII
ORF and the junction area between EMCV IRES and the
DHFR ORF. Endogenous PPIB gene region, presumably
unique in the CHO cells genome, was used as a single-
copy control amplicon. For oligoclonal cell populations
elevation of the transgene copy number during the first
Table 1 Cell lines, secreting FVIII
Cell line name Steps of selection and target gene amplification by MTX FVIII concentration, IU/ml Specific productivity, μIU/cell/day
3-B8 50 nM 5.4 ± 0.4a -
3-B8 1 K 50 nM→ 500 nM→ 1 μM 20.1a -
3-B8 2 K 50 nM→ 500 nM→ 2 μM 18.8a -
3-B8 1 K 2 K 50 nM→ 500 nM→ 1 μM→ 2 μM 17.6 -
3-B8 1 K 4 K 50 nM→ 500 nM→ 1 μM→ 4 μM 18.6 -
13B4F 50 nM→ 500 nM→ 1 μM→ 2 μM→ cloning 39.0 ± 5.5 11.8
11A4H 50 nM→ 500 nM→ 1 μM→ 2 μM→ cloning 39.4 ± 3.4 14.2
21A7B 50 nM→ 500 nM→ 1 μM→ 2 μM→ cloning 34.4 ± 0.8 11.8
a- FVIII concentration determined by ELISA
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step of the MTX-driven transgene amplification and sub-
sequent changes of this number in both directions are seen
(Fig. 2a and c), but the observed FVIII:C levels remain
mostly unchanged (Table 1). The transgene copy number
for the lead clonal cell lines was not proportional to their
specific productivity. Moreover, the transgene copy num-
ber for all three lines was strongly reduced compared to
the parent oligoclonal line (Fig. 2b and d). Apparently, a
significant portion of genomic inserts that occurred during
the MTX-driven amplification was unstable or transcrip-
tionally inactive. It should be noted that the copy number
of the expression cassette in the genome of best-producing
cell line 11A4H is moderate, only about 30 copies per hap-
loid genome. While for CMV promoter-based producer
cell lines, hundreds or even thousands of target gene cop-
ies per haploid genome were described elsewhere [25].
To ensure that genomic copies of inserted expression
cassette in the candidate cell line 11A4H did not undergo
large rearrangements (deletions) during the MTX-driven
gene amplification process the genomic DNA isolated
from A11H4 line was analyzed by PCR amplification of
the whole FVIII ORF region using temperature gradient.
The single PCR product corresponding to the full-length
ORF (4818 bp) was observed, no truncated forms were de-
tected. So we could conclude that all genome-integrated
copies of the expression cassette contain the intact FVIII-
BDD ORF without large deletions. (Fig. 3a). PCR product
was also cloned and three plasmid clones were subjected
to complete sequencing of the insert. All clones contained
correct ORF of the FVIII without mutations, so we have
assured that 11A4H cell lines codes only for correct FVIII
protein (data not shown). Absence of incorrectly spliced
or truncated FVIII mRNA was confirmed by PCR of total
cDNA with temperature gradient, also showing single spe-
cific product of the right size (Fig. 3b).
Consistency of the genetic inserts in the genome of
the candidate cell line 11A4H and the backup cell line
21A7B was investigated by Southern blotting using the
FVIII-BDD ORF-specific probe (Fig. 3c) and another
probe specific for the IRES, DHFR and the area of the
bla gene (Fig. 3d). Single hybridization band of the cor-
rect size (app. 3700 bp) was observed for the FVIII-BDD
ORF probe, indicating that both cell lines contain no
truncated sequences of the target gene. In the case of
IRES, DHFR, bla probe, three hybridization bands were
visible. Two of them correspond to the predicted size of
the restriction fragments, containing the IRES-DHFR
area of the genetic cassette (app. 2200 bp) and the
complete “bacterial maintenance” region of p1.1-F8BDD
plasmid (2900 bp). Thus IRES-DHFR region apparently
remains connected to the FVIII-BDD ORF sequence;
this conclusion is confirmed by the qPCR data on copy
numbers for FVIII and IRES-DHFR amplicons.
Third hybridization band had the size of app.
1500 bp and could correspond to the junction area
between the “bacterial maintenance” region of the
plasmid and the host cell DNA or to the junction be-
tween tandem copies of the genetic insert. We can
assume that IRES-DHFR area of the p1.1-F8BDD
plasmid remained intact in the genome of the
A11A4H cell line and the non-functional “bacterial
maintenance” region of the plasmid was present in
both intact and truncated form. Our data cannot rule
out the presence of unexpected genome integration
Fig. 2 qPCR analysis of the expression cassette copy numbers per haploid genome. Panel a - average copy number increase during MTX-driven
amplification in oligoclonal cell lines. Panel b - expression cassette copy number per haploid genome for clonal lines 13B4F, 11A4H, 21A7B. Panels
c, d - copy numbers for the control sequence (PPIB), supposedly unique to the CHO genome. ID- primers toward IRES-DHFR region, F8B - primers
toward FVIII-BDD ORF. Positions of the amplicons on the plasmid are depicted on Fig. 1a. One representative experiment from 3 is shown. Error
bars represent standard deviation, n = 3
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points in the areas of the EEF1A1 UFR and EEF1A1
DFR parts of the plasmid. Due to the presence of the
same DNA sequences in the genome of untransfected
host cells, the genome insertion events of the EEF1A1
UFR and EEF1A1 DFR parts of the plasmid cannot
be confirmed by Southern blotting and will be add-
itionally studied by the new generation sequencing
methods.
Relative levels of FVIII mRNA for three lead cell lines
(Fig. 4a) were not proportional to their specific produc-
tivities, indicating that actual secretion level of FVIII is
not simply limited by the transcribed mRNA levels. At
the same time, relative level of FVIII mRNA in the par-
ental line 3-B8 is at least 2.5 times lower, than in the
clonal lines and the end-titer of FVIII for this line is ap-
proximately 6 times lower. Control clonal cell line DG-
BDDFVIII-18 [18], expressing essentially the same FVIII
molecule, coded by the CMV promoter-based plasmid,
has even lower level of FVIII mRNA and lower secreted
FVIII titer. Thus relatively high level of FVIII mRNA is
required for high secretion rate, although quantitative
levels of FVIII mRNA and the secreted protein are not
proportional.
It is known, that high levels of translation of FVIII
mRNA results in the retention of the immature FVIII
pro-protein in the ER and drives the activation of the
UPR (unfolded protein response) [26]. UPR is coupled
to oxidative stress induction and increased cell death
rate. These effects are much more pronounced in the
case of full-length FVIII overexpression, although they
are still detectable in the case of FVIII-BDD [26]. Com-
mon marker of the UPR activation is the up-regulation
of the BiP chaperone, which directly interacts with the
FVIII pro-protein in the ER. In two of the three lead cell
lines obtained by us levels of BiP mRNA were found to
be similar to the baseline (Fig. 4b). In the case of the
most productive cell line 11A4H, level of BiP expression
was increased approximately threefold. Similar increase
of the BiP level was described for the BHK cells, secret-
ing human FVIII at the 2–3 IU/106 cells/d rate [26].
Modifications of the culture medium
The secretion level of several recombinant proteins can be
increased by adding sodium butyrate to the culture
medium [27]. Expression level of FVIII is also boosted by
sodium butyrate [28], probably due to inactivation of tran-
scription silencer, present in the mRNA of FVIII [29]. A
similar effect was described for sodium propionate
addition [24]. At the same time, addition of sodium butyr-
ate to the culture medium induces endoplasmic reticulum
stress in the FVIII-producing cells, as was shown in [19]
and damages the cells. Major consequence of endoplasmic
reticulum stress induction is the oxidative stress, which
Fig. 3 Integrity of the FVIII’s ORF in the genome DNA and mRNA of the 11A4H cell line and Southern blot analysis of genomic DNA. Panel a – PCR with
the annealing temperature gradient for genomic DNA from 11A4H cell line. Panel b – PCR for cDNA, prepared from 11A4H cell line and control un-
transfected CHO DG44 cells. Panel c – Southern blot analysis of genomic DNA from 11A4H and 21A7B cell lines and from un-transfected control. “FVIII
probe” - probe toward FVIII ORF, “IRES-DHFR-bla” – probe toward corresponding expression vector areas. Contrast for scans of developed membranes was
enhanced to add visibility. Red triangles depict annealing temperature gradients of 53 °C–68 °C for all reactions, DNA fragments sizes in bp. Expected size
of the correct PCR product – 4818 bp. Images of the agarose gels used for blotting are presented on the Additional file 4: Figure S3
Orlova et al. BMC Biotechnology  (2017) 17:33 Page 9 of 15
can be diminished by the membrane-permeable antioxi-
dant butylated hydroxyanisole (BHA).
We applied sodium butyrate and sodium propionate
supplements to batch cultures of 11A4H cells for 24 h.
In the case of sodium propionate treatment both FVIII:C
and VCD were decreased (Fig. 5a), but sodium butyrate,
used at 0.25 mM, allowed the increase of FVIII:C and
simultaneous decrease of VCD (Fig. 5b). Addition of up
to 0.5 mM of sodium butyrate allowed cell proliferation,
so 20% increase of volumetric productivity was recorded
for batch culture in the presence of 62.5 μM of sodium
butyrate (Fig. 5c) after 3 days of cultivation. Ratio of
procoagulant activity of secreted FVIII and its concen-
tration as ELISA antigen (FVIII:C/FVIII:Ag) was not af-
fected significantly by the addition of sodium butyrate
(Fig. 6a) up to 0.5 mM, indicating that sodium butyrate
does not damage the specific activity of the FVIII.
We measured levels of reactive oxygen species (ROS)
generation as a common marker of the oxidative stress
and found that the ROS level is directly proportional to
the concentration of sodium butyrate (Fig. 6c). The
addition of 10 μM BHA or 10% of fetal bovine serum
was sufficient to reduce the ROS generation level to
baseline values (Fig. 6d). At the same time, both specific
Fig. 5 Effects of sodium propionate, sodium butyrate and o-phospho-L-serine on FVIII:C level and cell growth of the 11A4H cell line. Growth time
is stated on corresponding panels. Cultures, presented on panels a, b, d were seeded at the VCD 1.4 × 106 cells/ml; panel c - 3.75 × 105 cells/ml.
Error bars indicate standard deviations, n = 2
Fig. 4 qPCR analysis of FVIII mRNA and expression levels of various housekeeping genes for clonal FVIII-secreting cell lines. Panel a – levels of FVIII mRNA
relative to β-actin mRNA. Panel b - expression levels of genes involved in protein synthesis and processing compared to the parent cell line CHO DG-44.
Sample “CMV-F8” on the panel a – clonal cell line DG-BDDFVIII-18, described in [18]. Data on the panel b normalized to β-actin. EiF1a1- eukaryotic
translation initiation factor 1a, EiF3- eukaryotic initiation factor 3, PPIB- peptidyl-propyl isomerase B, BIP –immunoglobulin-binding protein (BiP, Grp78);
OSTC- oligosaccharyltransferase complex subunit; St3gal – ST3 beta-galactoside alpha-2,3-sialyltransferase 3; B4gal - beta-1,4-galactosyltransferase 1. FIXp –
control line producing factor IX. One representative experiment from 3 is shown. Error bars represent standard deviation, n= 3-4
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productivity and volumetric productivity in the 96 h
batch culture of 11A4H cells were significantly increased
(Fig. 6b). Thus the volumetric productivity of the 11A4H
cell line in the batch culture can be almost doubled by
using non-toxic and inexpensive medium supplements.
Membrane-bound fraction of the secreted FVIII
Significant fraction of the secreted FVIII binds to the cell
membrane, preferably to the acidic phosphatidylserine-
containing membranes [30]. In the case of full-length
FVIII, membrane-bound fraction was estimated as ¾ of all
extracellular FVIII [16] and in the case of FVIII-BDD it
may increase up to 90% [31]. Membrane-bound FVIII-
BDD may be liberated during the cultivation by the
addition of vWF, annexin V or water-soluble phosphati-
dylserine analogue — o-phospo-L-serine [32]. Membrane-
bound FVIII also may be dissociated from the cell
membrane by the hypertonic solution with 20–30 mM
CaCl2 [32]. Both commercialize preparations of the full-
length FVIII are manufactured in the presence of vWF in
the culture medium, realized as co-expression of human
vWF [10] or addition of human plasma proteins to the
culture medium [9]. The presence of vWF in the culture
medium diminishes the membrane-bound fraction of
FVIII and protects the secreted FVIII from proteolytic
degradation. It should be completely removed during the
purification, thus increasing the complexity of down-
stream procedures and in-process controls. Commercial-
ized process of obtaining the FVIII-BDD SQ does not
involve the use of vWF in any form; and therefore the bio-
analogues of FVIII-BDD SQ are expected to be completely
free of vWF. Annexin V is the intracellular protein tightly
binding to the acidic membranes, its use in the industrial
process of FVIII production also seems non-practical. At
Fig. 6 Induction of oxidative stress by the sodium butyrate and its prevention by the BHA or fetal bovine serum increases volumetric productivity of
the 11A4H cell line in batch culture. Panels a, c – batch cultivation in the presence of sodium butyrate, 72 h. Panels b, d – batch cultivation in the
presence of 0.5 mM sodium butyrate (But), 10 μM BHA (BHA), 10% FBS (FBS), 0.1 mM H2O2 (H2O2), 96 h. Panels c, d – flow cytometry analysis of DCF-
stained cells, samples match those on panels a, b. Cells were seeded at 3.75 × 105 cells/ml. Data are presented as mean ± standard deviations, n = 2–3.
The statistical significance of the difference between groups was calculated by the unpaired t-test (* - P < 0.05; ** - P < 0.01). The difference was
assessed between the “intact” or “0 mM” group and other groups, if not indicated by brackets
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Fig. 7 (See legend on next page.)
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the same time, the addition of o-phospho-L-serine to the
culture medium is not expected to alter the downstream
process or to increase the cost of cultivation significantly.
The proportion of the membrane-bound FVIII:C, lib-
erated by NaCl + CaCl2 treatment according to [32], for
11A4H cell line was below 15% in all cases, including
the culture, induced by sodium butyrate (data not
shown). Addition of fetal bovine serum, containing bo-
vine vWF, enhanced FVIII:C level in the culture medium
(growth time 72 h) by about 60% (Fig. 6a). We suggest,
that this modest increase of FVIII:C level is the result of
FVIII protection from proteolytic breakdown by the
fWF. Similarly, the addition of o-phospho-L-serine to
the culture medium caused no increase in the FVIII:C
level, however, it caused the decrease of VCD (Fig. 5d).
We believe that the lack of phospho-L-serine effect we
observed was due to the low content of phosphatidylser-
ine in the cell membrane of 11A4H cells.
BDD-FVIII purification and characterization of the
recombinant protein
Purification of FVIII from the culture medium was per-
formed using the five-stage chromatography process,
including the solvent/detergent viral inactivation step.
SDS-PAGE analysis and Western blotting of the protein
fractions collected after the first three purification stages
are shown on Fig. 7a and b, the purification balance sheet
is shown in Table 2. Although the visually homogeneous
FVIII was obtained after the first three chromatography
steps, the specific procoagulant activity of FVIII was sig-
nificantly increased by subsequent anion exchange chro-
matography and size exclusion chromatography steps.
The specific procoagulant activity of the completely puri-
fied product is comparable to the specific activity of the
pharmaceutical grade FVIII-BDD SQ (7’600–13’800 IU/
mg protein, according to [33]). The total yield of the FVIII
protein (as measured by the procoagulant activity) was
above 20%, which proves that the purification process
employed is industrially applicable.
Tryptic peptides of the purified BDD-FVIII were ana-
lyzed by MALDI-TOF mass spectrometry. Mass spectra
of tryptic peptide mixtures of the two chains of BDD-
FVIII or of the single-chain FVIII form did definitely show
peaks corresponding to 44% of total BDD-FVIII protein
length (Fig. 7c). None of the mass-spectra, obtained in the
positive mode, contained peaks corresponding to the pep-
tide with three sulfotyrosine residues and the peptides
with three fully occupied N-glycosylation sites. At the
same time, we identified unmodified peptides, containing
partially occupied O- glycosylation sites and peptides with
T1651 and T1652 normally sulfated tyrosine residues.
Thus the purified BDD-FVIII sample contains a fraction
of molecules with non-sulfated tyrosine residues T1651
and T1652.
Discussion
Specialized plasmid vector p1.1, containing non-coding
areas of the EEF1A1 gene from Chinese hamster and
fragment of the terminal repeat of the Epstein-Barr virus
allowed us to obtain cell lines, secreting high quantities
of B-domain deleted FVIII in serum-free medium. Volu-
metric productivity of the clonal candidate cell line
11A4H created reached 39 IU/ml in the simple batch
culture and was increased up to 75 IU/ml by induction
with sodium butyrate and BHA. Previously we have cre-
ated several FVIII BDD secreting cell lines using the
standard CMV-based plasmid and the same transgene
amplification technique [18]. These lines secreted about
0.5 IU/ml of the FVIII-BDD. The use of the specialized
plasmid vector p1.1 instead of the standard vector
allowed us to increase the product titer 80-fold. Other
studies of the FVIII-BDD producing cell lines also report
lower levels of the active protein in the culture medium;
for example Chun et al. [24] reported a peak titer of
(See figure on previous page.)
Fig. 7 Analysis of the purified FVIII-BDD. Panel a - FVIII purification steps by SDS-PAGE. Panel b – Western blotting of purified FVIII. Panel c - tryptic peptides,
identified by MALDI-TOF mass spectrometry. M – marker; MMC wash – wash fraction stage 1; SP el – elution fraction stage 2; VIII ff – flow-through fraction
stage 3; VIII el – elution fraction stage 3. HC – heavy chain, LC – light chain. SDS-PAGE in reducing conditions, molecular weights are shown in kDa. Images
were contrast enhanced to add visibility. Identified peptides are marked in yellow
Table 2 FVIII purification sheet














0 Clarified medium - 320 – 36.3 - 11.6 - -
1 Multi-mode anion exchange Capto MMC 17 0.233 496.9 2133 8.45 73% 73%
2 Cation exchange SP Sepharose 10 0.271 538.1 1986 5.38 64% 46%
3 Affinity VIII Select 11 0.046 382.0 8304 4.20 78% 36%
4 + 5 Anion exchange + size exclusion Capto Q + Superdex 75 10 0.026 284.1 10925 2.84 68% 24%
a1–3 protein by Bradford; stage 4 + 5 by OD280 nm
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10 IU/ml of the FVIII BDD after treatment of the cell
culture by the sodium propionate and around 2 IU/ml
for the untreated culture. These data show that the plas-
mid used in the present study allows much higher secre-
tion rates of the FVIII than standard CMV-based
vectors.
After the multi-step procedure of transgene amplifica-
tion, most of the genome-integrated copies of the FVIII
ORF remained intact and linked to the ORF of the selec-
tion marker. This demonstrates the ability of the p1.1
vector to withstand the fragmentation of the genetic cas-
sette upon long-term exposure to the selection agent.
The selected clonal cell line showed no tendency to de-
crease the specific productivity for more than 70 genera-
tions without the selective pressure, demonstrating the
absence of target gene silencing. The target protein, the
B-domain deleted FVIII was purified to the specific ac-
tivity of the pharmaceutical product with the 24% yield
and characterized by mass spectrometry. The cell line
created can be employed for the economical production
of the bio-analogue FVIII for hemophilia A treatment.
Conclusion
The results obtained show that a specialized plasmid vec-
tor based on the EEF1A1 gene is suitable for the develop-
ment of highly productive and stable clonal cell line,
secreting the large therapeutically relevant protein - blood
clotting factor VIII. Additionally, we have found that the
created cell line secretes factor VIII to the culture medium
without significant binding of the product to the cell mem-
brane. Novel genetic constructions for the expression of
heterologous proteins combined with the optimized culti-
vation method allowed to obtain the secretion level of bio-
logically active recombinant FVIII increased almost tenfold
as compared with the previously published analogues.
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